Sign in
Taking people in SwedenPhase 3

Compares immunotherapy before surgery for melanoma that can be removed by surgery

Compares anti-PD-1 alone with anti-CTLA-4 plus anti-PD-1 before melanoma surgery.

Key facts

Who runs it
Karolinska University Hospital
Where
Goteborg, Linkoping, Lund, Orebro, Solna, and Umea, SwedenSee the 6 sites
Registry title
SWE-NEO: Swedish NeoAdjuvant Trial Comparing anti-PD-1 Monotherapy to Combined anti-CTLA-4/anti-PD-1 blockade in Resectable Stage III Melanoma
Status
Recruiting
Phase
Phase 3
People taking part
128 people, planned
Started
10 Jun 2025
Expected to end
31 Dec 2032
Type of study
Interventional
Record updated
10 September 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with stage III melanoma that can be fully removed by surgery. It compares two immune therapies given before the operation.

Age
18 years or older
Sex
All sexes
Disease stage
Stage III melanoma confirmed under the microscope that can be fully removed by surgery with clear margins. Up to 3 removable in-transit metastases are allowed. Skin, acral or unknown primary melanoma is accepted.
Earlier treatment
No earlier targeted therapy against BRAF and/or MEK. No earlier immunotherapy against CTLA-4, PD-1 or PD-L1.

Main reasons for not taking part

  • Melanoma that cannot be removed by surgery
  • Uveal, ocular or mucosal melanoma
  • Pregnant or breastfeeding women
  • Treatment with steroids above 10 mg daily prednisone equivalents or other immune-suppressing drugs within 14 days of study drug
  • Serious or uncontrolled medical conditions

The registry criteria, word for word

Show all 16 criteriaShow less

Who can take part

  • Participants must be at least 18 years of age
  • No prior targeted therapy targeting BRAF and/or MEK
  • Can provide a signed informed consent as described in the protocol, including compliance with the requirements and restrictions listed in the ICF and in this protocol
  • World Health Organization (WHO) Performance Status 0 or 1
  • Patients must have a. Histologically or cytologically confirmed Stage III melanoma. In the case of in-transit metastases (with or without lymph node metastases)‚ ≤3 resectable in-transit metastases are allowed. b. Patients with cutaneous, acral, or unknown primary melanomas are eligible for enrollment. c. Resectable tumors are defined as having no significant vascular, neural or bony involvement. Only patients where a complete surgical resection with tumor-free margins can safely be achieved are defined as resectable
  • Female patient of childbearing potential should have a negative urine or serum pregnancy test within 72 hours prior to receiving the first treatment. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
  • Female patients of childbearing potential must be willing to use a highly effective method of contraception, for the course of the study through 150 days after the last dose of study medication. Note: Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subject. Highly effective methods of contraception include one or more of the following: a. male partner who is sterile (vasectomised) prior to the female study subject’s entry into the study and is the sole sexual partner for the female subject; b. hormonal (oral, intravaginal, transdermal, implantable or injectable) c. an intrauterine hormone-releasing system (IUS) d. an intrauterine device (IUD) with a documented failure rate of < 1%
  • Male patients of childbearing potential must agree to use an adequate method of contraception, starting with the first dose of study therapy through 150 days after the last dose of study therapy. Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subject. A unique female sexual partner must postmenopausal, permanently sterilized (e.g. hysterectomy or tubal ligation), or use a highly effective method of contraception
  • No other malignancies, except if treated with curative intent and with a cancer-related life expectancy of more than 5 years
  • No prior immunotherapy targeting CTLA-4, PD-1 or PD-L1

Who cannot take part

  • Subjects with a condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days of study drug administration. Inhaled or topical steroids and adrenal replacement doses > 10 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease
  • Any serious or uncontrolled medical conditions that, in the investigator's opinion, may increase the risk associated with study participation or study drug administration, impair the ability of the subject to receive protocol therapy (including operation), or interfere with the interpretation of study results
  • Any condition that potentially hamper compliance with the study protocol and follow-up schedule; those conditions should be discussed with the subject before registration in the trial
  • Unresectable melanoma
  • Uveal/ocular or mucosal melanoma
  • Women who are pregnant or breastfeeding

Where in Sweden

  • Sahlgrenska University Hospital-Vaestra GoetalandsregionenGoteborg, SwedenTaking people
  • Region OestergoetlandLinkoping, SwedenTaking people
  • Region Skane Skanes UniversitetssjukhusLund, SwedenTaking people
  • Region Oerebro LaenOrebro, SwedenTaking people
  • Karolinska University HospitalSolna, SwedenTaking people
  • Region VaesterbottenUmea, SwedenTaking people

About the trial

What the trial wants to find out

To study event-free survival (EFS) in patients with resectable stage III melanoma, receiving two different neoadjuvant immune checkpoint inhibitor (ICI) regimens, combined anti-CTLA-4/anti-PD-1 blockade or anti-PD-1 monotherapy.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
SWE-NEO: Swedish NeoAdjuvant Trial Comparing anti-PD-1 Monotherapy to Combined anti-CTLA-4/anti-PD-1 blockade in Resectable Stage III Melanoma
Plain-language title
Compares immunotherapy before surgery for melanoma that can be removed by surgeryGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 9 November 2026.
Record updated
10 September 2026